Back to catalogue
№ 035 29 filings · 2021-09-30 → 2026-10-12

ACTIVEOPS PLC

AOM
Technology Share price 103p Market cap £74m Overall fit 520 /1000

Genuine high-fixed-cost SaaS with strong balance sheet and a credible operating-leverage path, but AI-receiver angle is thin (product marketing more than quantifiable AI-driven revenue), and the just-realised customer-concentration shock introduces downside asymmetry that caps conviction. Reasonable partial fit, not a core strategy name.

Fair value range 150p–210p Mid case · £129m
Absolute upside +75.4% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean SaaS disclosure; ARR, NRR, cash all transparently reported
  • Multi-year in-line-to-beats track record anchors trend assumptions
  • Fortress balance sheet makes downside bounded
Limits the call
  • Just-announced FY28 downgrade and unclear whether more customer losses follow
  • Material inconsistency between stated market cap (£161.4m) and apparent current price (111p)
Methodology

Forward EV/revenue multiple cross-checked vs EV/EBITDA

In one line · bull case

High-margin vertical SaaS with a fortress balance sheet and genuine operating-leverage path to the £100m ARR ambition, available at a reasonable price if the October-2026 setback is contained to the one customer disclosed.

In one line · biggest risk

If the October-2026 non-renewal signals wider customer-concentration erosion rather than a one-off, FY28 EBITDA could compress materially and the operating-leverage thesis stalls.

Drivers
AI beneficiary 45 /100
Markets itself as AI-powered SaaS and benefits indirectly from clients needing to measure AI productivity gains, but no AI-attributable revenue line disclosed.
Operating leverage 70 /100
84% gross margin, 90% SaaS gross margin, largely fixed cost base — classic SaaS leverage, dampened only by the still-small revenue scale.
Earnings vs expectations 50 /100
Four years of in-line-to-beats then a material October 2026 FY28 downgrade — pulls the composite from positive to neutral.
Growth momentum 45 /100
Was accelerating sharply (FY26 +48%) but FY28 now expected significantly below prior consensus.
Moat 50 /100
Deeply embedded in customer operations with 15–20 years of methodology and data, but limited structural moat beyond switching cost.
Earnings quality 70 /100
Clean reporting with transparent adjusted and statutory bridges; some noise from Enlighten acquisition costs.
Management quality 55 /100
Long-tenured Executive Chair with credible operating record; Enlighten acquisition execution partially impaired.
Cyclicality 30 /100
Enterprise SaaS to regulated financial services and healthcare — low cyclical sensitivity, procurement delays aside.
Leverage 8 /100
£19.6m net cash, debt free, plus trademark sale proceeds — fortress balance sheet.
Value-trap signals · 4
  • Customer concentration — single customer non-renewal = ~9% of ARR
  • Second customer loss in acquired Enlighten business within 12 months of deal
  • FY28 guidance cut materially after a run of upgrades
  • No dividend or buyback despite net cash > 10% of market cap

ActiveOps PLC (AIM: AOM) — Research Note

Executive summary

ActiveOps is a UK-based SaaS provider of "Decision Intelligence" software for large back-office operations in banking, insurance, healthcare administration and BPO (ControliQ / WorkiQ / CaseWorkiQ), monetised via recurring per-user subscriptions. Over the five-year filing period the Group transitioned from a sub-scale IPO-vintage story (£22m revenue, loss-making in FY22) into a reaccelerating, profitable scaled SaaS (£45m revenue, £4.2m adj EBITDA FY26) via organic +28% growth and the Enlighten acquisition — before the thesis was abruptly interrupted on 12 October 2026 by notice of non-renewal from a £3.8m-ARR customer, triggering a one-day share-price fall of roughly 50% and a cut to FY28 expectations. The single most important valuation point today is that at the pre-announcement capitalisation (£161m), investors were paying full price for a thesis that has just been meaningfully impaired, while the post-announcement price (c.111p) now embeds considerable pessimism about the quality of the remaining business.

Fair value estimate

  • Fair value range: 150p – 210p per share, mid 180p (£108m – £151m market cap, mid £129m).
  • Methodology: Multiple of forward revenue + sanity-check vs EV/EBITDA. Base assumption set:
    • FY27 revenue £47–50m (per management-reiterated guidance 2026-10-12 H1 FY27 update); adj EBITDA £5.0–6.4m; net cash FY27-end c.£25–30m.
    • FY28 revenue £44–48m (strip £3.8m ARR; weak H1 FY27 new business reduces starting base) with adj EBITDA £4.5–6.5m depending on cost actions.
    • Core SaaS deserves ~2.5–3.5x EV/revenue for a 10–15% organic SaaS grower with high gross margin and strong balance sheet, offset by freshly dented confidence in retention — anchor 2.75x on ~£48m = £132m EV, add ~£22m average net cash → £154m equity (≈ 215p). On a more bearish 2.25x and higher execution-risk discount: £108m (≈ 150p).
    • Cross-check: EBITDA mid ~£5.5m × 20x = £110m + £25m cash ≈ £135m (188p).
  • vs £161.4m stated market cap: fair-value mid implies ~20% downside at the stated/pre-crash cap (mid 180p < implied 225p). vs the apparent post-announcement price of 111p (£80m): fair-value mid implies ~60% upside — the stock looks cheap on fundamentals if the one-customer loss is the only shoe to drop. The task metadata locks in £161.4m, so the headline absolute return reads modestly negative, but the real question is which price the reader is actually looking at.

Sector context

  • Sector: Technology — Software & Computer Services. Confirmed consistent with ICB classification.
  • Peer profile: Enterprise vertical SaaS at the small end of AIM. Growth and margin profile is in line with typical scaled UK SaaS peers — ARR growing ~15% organic, 84% gross margin, EBITDA margin trajectory from loss-making to ~9%. Balance sheet (net cash, debt free) is above typical AIM SaaS peers.
  • Listed comparators: Cerillion, Beeks Financial Cloud, Netcall (all AIM vertical SaaS, broadly similar scale and recurring-revenue profile).

Investment thesis

  1. High-quality, embedded enterprise SaaS at an AIM small-cap discount. Organic SaaS +19% in H1 FY27 and ex-Enlighten NRR of 110% show the core business still compounds via upsell to tier-1 bank/insurer/BPO customers; SaaS gross margin reached 90% and the migration to higher-tier series 3/4/5 is still a tailwind 2025-11-27 Interim; 2026-10-12 H1 FY27 update.
  2. Fortress balance sheet and genuine cash generation. £19.6m cash at Sept-2026, zero debt, plus $10m received in April 2026 for the trademark sale strengthens optionality for buyback, M&A or defensive insulation against the FY28 shortfall; management reaffirmed continued investment despite the setback 2026-04-21 FY26 update; 2026-10-12 H1 FY27 update.
  3. Credible operating-leverage path to the £100m ARR / 25% EBITDA margin ambition. Capital Markets Day articulated a medium-term model where recurring revenue scales against a largely fixed R&D / central cost base; EBITDA already doubled YoY in H1 FY26 while revenue grew 45% 2025-11-04 Capital Markets Day; 2025-11-27 Interim.

Key risks

  1. Customer-concentration shock, now actually realised. A single contract worth £3.8m ARR (~9% of Group ARR) will not renew in March 2027 and new-business momentum weakened in H1 FY27 — this is the exact scenario a small-cap vertical SaaS stock cannot absorb easily 2026-10-12 H1 FY27 update. There may be further undisclosed concentration (one US BPO EMEIA customer previously announced partial reduction in H1 FY25 before reversing).
  2. Enlighten acquisition execution is already fraying. Within 10 months of the June-2025 deal, an Enlighten customer notified intention to terminate, triggering an estimated £3.5m reduction in deferred consideration; this is the second customer-loss event in the enlarged group within a year 2026-04-21 FY26 update; 2025-11-27 Interim.
  3. AI-receiver thesis is more marketing than substance so far. Management's AI framing has shifted from "underpinned by 15+ years of operational data" to "20+ years" and "measure productivity gains from AI" rhetoric, but no filing points to a quantified AI-driven revenue line or margin uplift beyond the standard product-tier upgrade cycle 2025-11-27 Interim; 2026-10-12 H1 FY27 update.

Operating leverage

This is a textbook high-fixed-cost SaaS cost structure: group gross margin ~84%, SaaS gross margin ~90%, R&D expensed through the P&L (with modest capitalisation of ~£1m per half), and sales/central costs largely fixed relative to incremental ARR. The H1 FY26 → H1 FY27 progression — revenue +45% then +21% while adj EBITDA grew 100% then double-digit — shows the leverage is live. On the current cost base, management's stated medium-term ambition of 25% EBITDA at £100m ARR implies £25m EBITDA versus £4.2m today, i.e. roughly £15m of fresh EBITDA on ~£58m of fresh ARR, which is a contribution margin of ~26%+ on incremental revenue after reinvestment, and plausibly 50%+ on strictly marginal SaaS seats. A 10–20% revenue beat above planned FY28 (say £5–10m incremental) could add £1.5–4m to EBITDA (~30–70% EBITDA uplift) — real leverage, though not the "multiples of profit" that a bigger platform would deliver, because the central cost base is still relatively heavy at this scale and part of any beat would be reinvested in sales capacity.

Value-trap signals

  • Customer concentration risk now visible (one customer = ~9% ARR exiting; second customer in the acquired Enlighten business terminated).
  • Acquisition integration pain — £1.4m acquisition costs plus £1.2m restructuring, and deferred consideration already revised down.
  • Guidance was raised multiple times in FY26 then abruptly cut for FY28 — pattern of over-promising within a single twelve-month window.
  • No dividend, no buyback despite net cash > 10% of mcap — capital returned via M&A whose returns are now partially impaired.

Earnings vs. expectations

  • FY23 (Apr-2023 update): Revenue ~£25m vs consensus £24.6–25.1m, EBITDA positive vs consensus £(0.5)m loss — beat.
  • FY24 (Apr-2024 update): Revenue £26.8m vs analyst range £27.3–27.4m — slight miss on revenue; EBITDA £2.2m vs £1.0–1.3m — beat on profit.
  • H1 FY25 (Oct-2024 update, Nov-2024 interim): Delivered in line with FY expectations; +10% revenue, +32% EBITDA — in line / modest beat.
  • FY25 (Apr-2025 update): Revenue £30.4m vs implied consensus, +13% — in line; EBITDA flat YoY as planned reinvestment.
  • H1 FY26 (Oct-2025 update): Revenue "comfortably ahead" of £40.3m consensus — beat.
  • FY26 (Apr-2026 update): Revenue £45.0m vs £43.0m consensus; adj EBITDA £4.2m vs £3.9m — beat.
  • H1 FY27 (Oct-2026 update): In-line but FY28 "significantly below" expectations — first material miss / downgrade.

Pattern: four years of in-line-to-beats, culminating in a cumulative upgrade cycle, then one sharp downgrade in October 2026. This is important context — ActiveOps' track record is good, but Oct-2026 is the first time management has moved expectations materially the wrong way.

Conviction

Conviction: 3 / 5 (moderate).

  • Anchors (supporting confidence): clean financial disclosure with full balance sheet and cash-flow statements in each interim; mature recurring-revenue model where ARR is directly observable; broadly consistent management commentary across the five-year period.
  • Caveats (limiting confidence): fair value is highly sensitive to the FY28 cost-action outcome and to whether more customers follow the one just lost (which the filings cannot tell me); and the share-price data appears inconsistent with the stated market cap (111p × 71.7m shares = c.£80m vs the stated £161.4m), so where "current price" sits for the reader materially affects the stated upside.
Filings consulted · 32

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-10-12H1 Fy27 Trading Update And Notice OF Results2026-10-12_9816803_h1-fy27-trading-update-and-notice-of-results.md0.85
  2. 2026-09-30Result OF Agm2026-09-30_9799448_result-of-agm.md0.30
  3. 2026-08-21Posting OF Annual Report And Notice OF Agm2026-08-21_9734409_posting-of-annual-report-and-notice-of-agm.md0.95
  4. 2026-04-21Full Year Trading Update And Notice OF Results2026-04-21_9529261_full-year-trading-update-and-notice-of-results.md0.85
  5. 2025-11-27Interim Results2025-11-27_9259946_interim-results.md0.77
  6. 2025-11-04Capital Markets Day2025-11-04_9210202_capital-markets-day.md0.81
  7. 2025-10-15H1 2026 Trading Update And Notice OF Results2025-10-15_9171327_h1-2026-trading-update-and-notice-of-results.md0.72
  8. 2025-09-29Result OF Agm2025-09-29_9138040_result-of-agm.md0.20
  9. 2025-09-04Notice OF Agm2025-09-04_9087993_notice-of-agm.md0.20
  10. 2025-04-24Full Year Trading Update And Notice OF Results2025-04-24_8843102_full-year-trading-update-and-notice-of-results.md0.55
  11. 2024-11-14Interim Results2024-11-14_8548917_interim-results.md0.58
  12. 2024-11-11Notice OF Analyst And Investor Presentations2024-11-11_8541003_notice-of-analyst-and-investor-presentations.md0.46
  13. 2024-10-17Trading Update And Notice OF Half Year Results2024-10-17_8491049_trading-update-and-notice-of-half-year-results.md0.58
  14. 2024-09-26Result OF Agm And Confirmation OF Board Changes2024-09-26_8442390_result-of-agm-and-confirmation-of-board-changes.md0.14
  15. 2024-08-22Notice OF Agm2024-08-22_8380355_notice-of-agm.md0.14
  16. 2024-04-24Full Year Trading Update And Notice OF Results2024-04-24_8153197_full-year-trading-update-and-notice-of-results.md0.38
  17. 2023-11-14Interim Results2023-11-14_7878863_interim-results.md0.41
  18. 2023-11-10Notice OF Investor Presentation2023-11-10_7872750_notice-of-investor-presentation.md0.32
  19. 2023-10-18Trading Update And Notice OF Half Year Results2023-10-18_7822972_trading-update-and-notice-of-half-year-results.md0.41
  20. 2023-09-28Result OF Agm2023-09-28_7784263_result-of-agm.md0.07
  21. 2023-08-23Publication OF Annual Report And Notice OF Agm2023-08-23_7713737_publication-of-annual-report-and-notice-of-agm.md0.24
  22. 2023-06-26Notice OF Results And Investor Presentation2023-06-26_7593726_notice-of-results-and-investor-presentation.md0.17
  23. 2023-04-25Full Year Trading Update2023-04-25_2974_full-year-trading-update.md0.21
  24. 2023-04-25Full Year Trading Update2023-04-25_7496993_full-year-trading-update.md0.21
  25. 2022-11-29Interim Results2022-11-29_7218864_interim-results.md0.23
  26. 2022-10-25Trading Update And Notice OF Half Year Results2022-10-25_7156742_trading-update-and-notice-of-half-year-results.md0.23
  27. 2022-09-29Result OF Agm2022-09-29_7170749_result-of-agm.md0.07
  28. 2022-08-08Publication OF Annual Report And Notice OF Agm2022-08-08_7012736_publication-of-annual-report-and-notice-of-agm.md0.24
  29. 2022-03-24Trading Update2022-03-24_7049839_trading-update.md0.21
  30. 2021-11-25Interim Results2021-11-25_6591321_interim-results.md0.23
  31. 2021-10-20Trading Update And Notice OF Results2021-10-20_6859957_trading-update-and-notice-of-results.md0.21
  32. 2021-09-30Result OF Agm2021-09-30_6645415_result-of-agm.md0.03

This research note was authored by a large language model after reading 29 regulatory filings published between 2021-09-30 and 2026-10-12. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.